Florencia Moreno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florencia Moreno has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Liliana Orellana
Deakin University, Biostatistics Unit, Faculty of Health, Geelong, Australia
2 shared publications Adriana Fandiño
Ophthalmology Service; Hospital JP Garrahan; Buenos Aires Argentina
1 shared publicationAriel Gualtieri
National Academy of Medicine, Buenos Aires City, Argentina
1 shared publicationBanafsheh Sinaki
Department of Pediatrics; New York Medical College; New York New York
1 shared publicationBenedetto Terracini
1 shared publicationDora Loria
1 shared publication
Latest Publications
- 2 May 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (8) , 1362-1367
Childhood Neuroblastoma: Incidence and Survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2012
Background There are reports indicating a low incidence of neuroblastoma (NB) in some developing countries but no conclusive data are available from population-based studies at a national level. Purpose To describe the incidence and survival of 971 patients with NB in Argentina with data from the National Pediatric Cancer Registry (ROHA), and the impact of age, gender, stage, regional, and socioeconomic indicators on outcome. Methods All cases of NB reported to ROHA (2000–2012) were the subject of the analysis. Annual-standardized incidence rate (ASR) was calculated using the National Vital Statistics and survival was estimated. The extended human development index (EHDI) was used as the socioeconomic indicator. Results ASR was 8.3/1,000,000 children (0–14 years) and remained stable along this period. Regional variation in ASR ranged from 3.4 in the Northwest to 9.8 in the Central region, being most marked in the first year of life. Five-year survival rate (SR) was 47%, with no sex difference. For patients older than 18 months, it was 36%, for stage IV 23%, for those born in the Northeast region 38%, and for those with an amplified MYCN 15%. Residents in provinces with a higher EHDI had a better 5-year survival (57% vs. 41% for lower EHDI) and higher ASR (12.3 vs. 5.6 for lower EHDI). Stage and MYCN status showed an independent inferior prognosis. Conclusions ASR of NB in Argentina is lower than in developed countries, with considerable regional variation. SRs are also lower than in developed countries.
- 2 May 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (8) , 1362-1367
Childhood Neuroblastoma: Incidence and Survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2012
Background There are reports indicating a low incidence of neuroblastoma (NB) in some developing countries but no conclusive data are available from population-based studies at a national level. Purpose To describe the incidence and survival of 971 patients with NB in Argentina with data from the National Pediatric Cancer Registry (ROHA), and the impact of age, gender, stage, regional, and socioeconomic indicators on outcome. Methods All cases of NB reported to ROHA (2000–2012) were the subject of the analysis. Annual-standardized incidence rate (ASR) was calculated using the National Vital Statistics and survival was estimated. The extended human development index (EHDI) was used as the socioeconomic indicator. Results ASR was 8.3/1,000,000 children (0–14 years) and remained stable along this period. Regional variation in ASR ranged from 3.4 in the Northwest to 9.8 in the Central region, being most marked in the first year of life. Five-year survival rate (SR) was 47%, with no sex difference. For patients older than 18 months, it was 36%, for stage IV 23%, for those born in the Northeast region 38%, and for those with an amplified MYCN 15%. Residents in provinces with a higher EHDI had a better 5-year survival (57% vs. 41% for lower EHDI) and higher ASR (12.3 vs. 5.6 for lower EHDI). Stage and MYCN status showed an independent inferior prognosis. Conclusions ASR of NB in Argentina is lower than in developed countries, with considerable regional variation. SRs are also lower than in developed countries.
- 1 August 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (4) , 505-510
Childhood cancer in Argentina: Survival 2000–2007
- 1 August 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (4) , 505-510
Childhood cancer in Argentina: Survival 2000–2007
- 11 April 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1610-1615
A population-based study of retinoblastoma incidence and survival in Argentine children
Background An increased incidence of retinoblastoma in some developing countries has been reported but no conclusive data are available from population-based studies at national level. Purpose To report the incidence and survival of retinoblastoma in Argentina from the National Pediatric Cancer Registry (ROHA) and the influence of socio-economical indicators on outcome. Procedure Cases reported to the ROHA (2000–2009) were analyzed. Incidence rates were calculated using National Vital Statistics and survival was estimated. The extended human development index (EHDI) was used as a socio-economical indicator. Results With 438 patients reported, an incidence of 5.0 cases per million children 0–14 years old (95% CI 3.5–6.4) was calculated. Median age at diagnosis was significantly higher for children from provinces with lower EHDI; (24 vs. 35 months for unilateral, (P = 0.003) and 9 versus 11.5 months for bilateral retinoblastoma (P = 0.027). The 3-year probability of survival was 0.87 and 0.94 for unilateral and bilateral retinoblastoma, respectively. Residents in provinces with higher EHDI had a better 3-year survival (0.93 vs. 0.77 for lower EHDI, P < 0.0001). Probability of survival was higher for patients treated at tertiary level institutions (P = 0.0015). The combination of low EHDI residence province with no treatment at a tertiary institution was associated with the worst survival outcome. For both, unilateral and bilateral disease, children who died were in average diagnosed at older age. Conclusions The incidence of retinoblastoma in Argentina is comparable to that of developed countries. Retinoblastoma is diagnosed later and survival is lower in the less developed areas of the country. Pediatr Blood Cancer 2014;61:1610–1615.
- 11 April 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1610-1615
A population-based study of retinoblastoma incidence and survival in Argentine children
Background An increased incidence of retinoblastoma in some developing countries has been reported but no conclusive data are available from population-based studies at national level. Purpose To report the incidence and survival of retinoblastoma in Argentina from the National Pediatric Cancer Registry (ROHA) and the influence of socio-economical indicators on outcome. Procedure Cases reported to the ROHA (2000–2009) were analyzed. Incidence rates were calculated using National Vital Statistics and survival was estimated. The extended human development index (EHDI) was used as a socio-economical indicator. Results With 438 patients reported, an incidence of 5.0 cases per million children 0–14 years old (95% CI 3.5–6.4) was calculated. Median age at diagnosis was significantly higher for children from provinces with lower EHDI; (24 vs. 35 months for unilateral, (P = 0.003) and 9 versus 11.5 months for bilateral retinoblastoma (P = 0.027). The 3-year probability of survival was 0.87 and 0.94 for unilateral and bilateral retinoblastoma, respectively. Residents in provinces with higher EHDI had a better 3-year survival (0.93 vs. 0.77 for lower EHDI, P < 0.0001). Probability of survival was higher for patients treated at tertiary level institutions (P = 0.0015). The combination of low EHDI residence province with no treatment at a tertiary institution was associated with the worst survival outcome. For both, unilateral and bilateral disease, children who died were in average diagnosed at older age. Conclusions The incidence of retinoblastoma in Argentina is comparable to that of developed countries. Retinoblastoma is diagnosed later and survival is lower in the less developed areas of the country. Pediatr Blood Cancer 2014;61:1610–1615.
- 1 January 2013
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (2) , 465-473
Childhood cancer: Incidence and early deaths in Argentina, 2000–2008
- 1 January 2013
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (2) , 465-473
Childhood cancer: Incidence and early deaths in Argentina, 2000–2008